Evolution of Rituximab as "standard" therapy in patients (pts) with newly diagnosed follicular (FL), mantle cell (MCL), and diffuse large B cell (DLCL) non-Hodgkin's lymphoma (NHL) in 5 United States comprehensive cancer centers: An analysis from the national comprehensive cancer network (NCCN) NHL outcomes project Meeting Abstract
| Authors: | Friedberg, J. W.; Kho, M. E.; Lepisto, E. M.; Rodriguez, M. A.; TerVeer, A.; LaCasce, A. S.; Nademanee, A. P.; Millenson, M.; Czuczman, M.; Niland, J.; Zelenetz, A. D.; Weeks, J. C. |
| Abstract Title: | Evolution of Rituximab as "standard" therapy in patients (pts) with newly diagnosed follicular (FL), mantle cell (MCL), and diffuse large B cell (DLCL) non-Hodgkin's lymphoma (NHL) in 5 United States comprehensive cancer centers: An analysis from the national comprehensive cancer network (NCCN) NHL outcomes project |
| Meeting Title: | 46th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 104 |
| Issue: | 11 Pt. 1 |
| Meeting Dates: | 2004 Dec 4-7 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2004-11-16 |
| Start Page: | 391A |
| Language: | English |
| ACCESSION: | WOS:000225127501394 |
| PROVIDER: | wos |
| PUBMED: | 15562524 |
| DOI: | 10.1182/blood.V104.11.1391.1391 |
| Notes: | Meeting Abstract: 1391 -- 46th Annual Meeting of the American-Society-of-Hematology -- DEC 04-07, 2004 -- San Diego, CA -- 1 -- Source: Wos |
